Tokyo, Japan
Tokyo, Japan

Time filter

Source Type

There is provided a labeling precursor compound represented by the following general formula (2): wherein R_(1 )represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R_(2 )and R_(3 )each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R_(6 )represents an alkyl group or CONR_(11)R_(12 )wherein R_(11 )and R_(12 )each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R_(4), R_(5), R_(7 )and R_(8 )each independently represent a hydrogen atom, an alkyl group or an alkoxy group.


There is provided a labeling precursor compound represented by the following general formula (2):_(1) represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R_(2) and R_(3) each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R_(6) represents an alkyl group or -CONR_(11)R_(12) wherein R_(11) and R_(12) each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R_(4), R_(5), R_(7) and R_(8) each independently represent a hydrogen atom, an alkyl group or an alkoxy group.


Patent
Nihon Medi Physics Co., Japan National Institute of Radiological Sciences and National Cancer Center | Date: 2014-07-02

A radiopharmaceutical comprising a particular radioactive dithiosemicarbazone copper complex, wherein the radiopharmaceutical is used for combined administration with a chelating agent, and wherein the chelating agent comprises a multidentate ligand having a maximum dentate number of 2 or more to 4 or less.


Patent
Nihon Medi Physics Co. | Date: 2015-10-01

It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [^(18)F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R^(1 )is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by OR^(2); R^(2 )is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R^(3 )is a protective group.


Patent
Nihon Medi Physics Co. | Date: 2015-08-21

It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [^(18)F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R^(1 )is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by OR^(2); R^(2 )is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R^(3 )is a protective group.


Patent
Nihon Medi Physics Co. | Date: 2014-04-09

It is intended to provide a compound that is effective as a diagnostic imaging probe that targets amyloid, and a diagnostic agent for Alzheimers disease comprising the compound. Provided are a compound represented by the following formula (1), or salt thereof:^(1) is a radioactive halogen substituent, A^(1) and A^(2) independently represent CH or N, and a diagnostic agent for Alzheimers disease, comprising the compound represented by the above formula or a salt thereof. The above compound and the above diagnostic agent for Alzheimers disease transfer into brain after administration, and indicate good accumulation on amyloid deposited in the brain.


Patent
Nihon Medi Physics Co. | Date: 2015-03-04

One of the preferred embodiments includes: (a) creating a summed 3D nuclear medicine imaging data by summing a plurality of 3D nuclear medicine imaging data pixel by pixel, wherein each of the plurality of 3D nuclear medicine imaging data is associated with a different phase of a cardiac cycle; (b) determining pixels corresponding to myocardial regions in the summed 3D nuclear medicine imaging data; (c) defining a plurality of tracing directions based on the summed 3D nuclear medicine imaging data, and determining a reference myocardial center base point, a reference inner myocardial wall base point and a reference outer myocardial wall base point for each of the tracing directions; (d) determining a phase-specific myocardial center base point for each of the tracing directions for each of the phases based on the corresponding 3D nuclear medicine imaging data; and (e) seeking a difference between the reference myocardial center base point and the phase-specific myocardial center base point, and determining a phase-specific inner myocardial wall base point and a phase-specific outer myocardial wall base point by shifting the reference inner myocardial wall base point and the reference outer myocardial wall base point respectively based on the determined difference, for each of the tracing directions for each of the phases.


Patent
Nihon Medi Physics Co. and Hokkaido University | Date: 2014-07-30

The present invention is a compound represented by the following formula (1) or a salt thereof. In the formula (1), R_(1) denotes a hydrogen atom, a methyl group, or a hydroxymethyl group, and n is an integer of 1 or 2.


Patent
Nihon Medi Physics Co. | Date: 2014-04-30

It is intended to provide a compound that is effective as a diagnostic imaging probe that targets amyloid, and a diagnostic agent for Alzheimers disease comprising the compound. Provided are a compound represented by the following formula (1), or a salt thereof:^(1) is a radioactive halogen substituent, 0 to 2 of A^(1), A^(2), A^(3) and A^(4) represent N, and the rest represent CH, and a diagnostic agent for Alzheimers disease which comprises a compound represented by the above formula (1) or a salt thereof. The present compound and the present diagnostic agent for Alzheimers disease transfer into brain after administration, and indicate good accumulation on amyloid deposited in the brain.


Patent
Nihon Medi Physics Co. | Date: 2014-04-07

It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [^(18)F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R^(1 )is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by OR^(2); R^(2 )is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R^(3 )is a protective group.

Loading Nihon Medi Physics Co. collaborators
Loading Nihon Medi Physics Co. collaborators